NewsRoom Articles - Page 17 of 154 - PsychedelicNewsWire (PNW)

MondayDec 18, 2023 10:59 am

Startup Secures US Patents for Synthetic Psychedelics

Terran Biosciences, a drug developer based in New York, announced recently that it had obtained patent approval for its psychedelic drugs from the U.S. Patent and Trademark Office. The drugs, which have been designed to treat neurological and psychiatric disorders, are based on psilocybin, namely psilocybin edisylate and psilocybin HCI. Terran Biosciences describes the drugs as the world’s first new polymorphs and salts of psilocybin, noting that the patents will include techniques for treating the aforementioned disorders. Dr. Sam Clark, Terran CEO and founder, stated that the company was approaching its goal of providing patients with accessible and affordable psilocybin…

FridayDec 15, 2023 11:13 am

FDA Assessing MAPS’ Application for MDMA as Treatment for PTSD

The MAPS Public Benefit Corporation (MAPS PBC), a psychedelics-focused, drug-development company, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA). MAPS PBC is asking the FDA to approve the use of MDMA (ecstasy, molly) as a prescription medication for treating post-traumatic stress disorder (PTSD). The company is requesting that the federal agency provide an expedited review of the psychedelic as the FDA had already designated it as a breakthrough therapy. The FDA granted breakthrough therapy designation for MDMA in PTSD treatment in 2017 and reached an agreement with MAPS to design two MDMA phase…

ThursdayDec 14, 2023 11:56 am

JAMA Article Suggests Psychedelics Industry Likely to Clash with FDA

Several states in the United States have already approved the use of psychedelics, even before the U.S. Food and Drug Administration (FDA) has concluded trials and drug approvals. For instance, the state of Oregon legalized the nontherapeutic use of psilocybin and established a program for supervised use following approval of Measure 109 by voters. Soon after this, voters in the state of Colorado approved Proposition 122, which will allow psychedelic businesses to launch come 2025. Other states planning to approve similar measures in 2024 include California, New York, Illinois, Vermont and Massachusetts. At the moment, the FDA is reviewing psychedelics…

WednesdayDec 13, 2023 12:05 pm

California Campaigners Submit Final Text of 2024 Psychedelics Legalization Ballot Measure

The campaign behind a ballot measure in California to legalize psychedelic substances has presented a final amended resolution to officials in the state. Various changes have been made to the initiative following a public comment period that concluded in November. For instance, the changes expanded the types of businesses that could operate and also required that larger psychedelics businesses acquire peace agreements with labor unions. In addition, under the revised measure, adults would be permitted to legally use, possess and grow psychedelics such as LSD, psilocybin, DMT, MDMA, mescaline and ibogaine. However, one would require a recommendation from a physician…

TuesdayDec 12, 2023 9:00 am

Longevity Movement Looks to Tap Benefits of Psychedelics

America’s longevity movement, a growing community of people committed to reversing aging, is the latest group to take notice of psychedelics. A recent surge of psychedelic-related studies has revealed that hallucinogenic drugs such as LSD, ayahuasca and psilocybin (magic mushrooms) have the potential to treat several mental disorders. These initial studies have found that psychedelics can be especially effective when paired with traditional talk therapy, offering long-term relief against hard-to-treat conditions, including post-traumatic stress disorder (PTSD), eating disorders and treatment-resistant depression, with few side effects and at minimal doses. The findings have been so promising that researchers and mental-health experts…

MondayDec 11, 2023 12:56 pm

AMA Study Shows Safety, Efficacy of Psilocybin in Treating Bipolar Depression

A new clinical study from the American Medical Association (AMA) has indicated that psilocybin-assisted psychotherapy may be safe and effective in the treatment of bipolar II disorder depressive episodes. The nonrandomized controlled study was conducted at Baltimore’s Sheppard Pratt Hospital and involved 15 patients diagnosed with treatment-resistant BDII depression with lengthy depressive episodes. After receiving a single psilocybin dose followed by seven psychotherapy sessions, researchers say study participants “displayed strong and persistent antidepressant effects” with no increase in mood instability of suicidality. Patients with bipolar II disorder (BDII) received a 25-milligram dose of psilocybin and had seven sessions with therapists…

FridayDec 08, 2023 3:55 pm

Researchers Explore Whether Ayahuasca Ceremonies Could Reduce Narcissistic Behavior

A study published in the “Journal of Personality Disorders” has suggested that participation in ayahuasca rituals may reduce narcissistic behavior. The research explored the connection between ayahuasca, a psychedelic brew with a rich history of spiritual, healing and religious use in indigenous Amazonian communities, and narcissistic behavior. Ayahuasca is typically brewed from the Banisteriopsis caapi vine and the leaves of plants containing dimethyltryptamine (DMT) such as Psychotria viridis. The brew triggers a potent hallucinogenic experience once ingested and is usually consumed in ritualistic ceremonies under the guidance of experienced shamans. A typical guided ayahuasca ceremony is meant to put participants…

ThursdayDec 07, 2023 2:44 pm

Psilocybin, LSD Could Be Better Than Opioids in Pain Management

A recent review of scientific psychedelic research has suggested that hallucinogens such as psilocybin (magic mushrooms) and LSD may be more effective at managing pain compared to opioids. The review indicates that classic psychedelics may be effective at mitigating the physical agony caused by pain disorders such as fibromyalgia and injuries. Furthermore, the review noted that the efficacy of these substances can increase over time because they can simultaneously help patients deal with symptoms of mental anguish as well, essentially killing two birds with one stone in a way traditional pain medications such as opioids never could. The past couple…

WednesdayDec 06, 2023 2:46 pm

Psilocybin Reduces Distress in Those Who Suffered Childhood Trauma

A Canadian study published in the “Journal of Psychoactive Drugs” has revealed that psilocybin, the main hallucinogenic agent in magic mushrooms, may reduce psychological distress in individuals with childhood trauma. The researchers found a possible association between magic mushroom use and declines in psychological distress, especially among people with adverse childhood experiences (ACE) after exploring the relationship between psychological distress and psilocybin use. Like several other classic psychedelics, psilocybin has been subject to increased attention in recent years, thanks to anecdotal and scientific claims of its medical efficacy. Previous research efforts have found that psilocybin may be effective at treating…

TuesdayDec 05, 2023 3:47 pm

Why Psychedelics Yield Meaningful Experiences

Psychedelics have been subject to intense public and scientific scrutiny in recent years, thanks to claims of their medical efficacy. Countless studies have now found that psychedelics can induce profound mental changes in patients with hard-to-treat mental disorders such as post-traumatic stress disorder (PTSD) and major depressive disorder, putting psychedelics such as MDMA, LSD and psilocybin on track to becoming approved mental-health treatments. However, long before scientists began running psychedelic clinical trials, regular and even casual psychedelics users knew one thing about this curious class of drugs: psychedelics could induce meaningful and often life-changing experiences in people who took them…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000